Skip to main content
Clinical Trials/NCT02735473
NCT02735473
Completed
Phase 2

Choline Supplementation as a Neurodevelopmental Intervention in Fetal Alcohol Spectrum Disorders

University of Minnesota1 site in 1 country46 target enrollmentJune 2016

Overview

Phase
Phase 2
Intervention
Choline bitartrate
Conditions
Fetal Alcohol Spectrum Disorders
Sponsor
University of Minnesota
Enrollment
46
Locations
1
Primary Endpoint
Elicited Imitation Memory Task - Short Delay Memory Measure: 6 Months
Status
Completed
Last Updated
3 years ago

Overview

Brief Summary

This is a randomized, double-blind, placebo-controlled trial of choline supplementation in children with Fetal Alcohol Spectrum Disorders (FASD). The primary outcome measures are cognitive measures.

Detailed Description

This project is the third in a series of randomized, double-blind placebo-controlled trials of choline bitartrate in children ages 2-5 who have been diagnosed with Fetal Alcohol Spectrum Disorders (FASD). Pre-clinical data suggests that choline may attenuate the cognitive deficits caused by prenatal alcohol exposure (especially memory deficits). This study will evaluate the effects of daily choline supplementation vs. placebo for 9 months. Outcome measures include an elicited imitation memory paradigm, global cognitive functioning, and aspects of executive functioning. The study will also continue to collect safety and tolerability data.

Registry
clinicaltrials.gov
Start Date
June 2016
End Date
September 10, 2021
Last Updated
3 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Ages 2 years to 5 years of age
  • Available parent or legal guardian capable of giving informed consent for participation.
  • Documented prenatal alcohol exposure (self-report, social service records, or adoption records).
  • Modified Institute of Medicine (IOM) criteria for Fetal Alcohol Syndrome (FAS), Partial Fetal Alcohol Syndrome (PFAS), or Alcohol-Related Neurodevelopmental Disorder (ARND) (Hoyme, May, et al., 2005).

Exclusion Criteria

  • Known history of a neurological condition (ex. epilepsy, traumatic brain injury)
  • Known history of a medical condition known to affect brain function.
  • Known history of other neurodevelopmental disorder (ex. autism, Down syndrome)
  • Known history of very low birthweight (\<1500 grams)

Arms & Interventions

Choline bitartrate

Powdered drink mix containing choline bitartrate 19 mg. per kg.

Intervention: Choline bitartrate

Placebo

Powdered drink mix containing matching placebo

Intervention: Placebo

Outcomes

Primary Outcomes

Elicited Imitation Memory Task - Short Delay Memory Measure: 6 Months

Time Frame: Change from baseline to 6 months in percentage correct

Elicited Imitation memory paradigm - short delay memory measure at 6 months; scores are in percentage correct.

Elicited Imitation Memory Task - Short Delay Memory Measure: 9 Months

Time Frame: Change from baseline to 9 months

Elicited Imitation memory paradigm - short delay memory measure at 9 months

Secondary Outcomes

  • Minnesota Executive Function Scale: 6 Months(Change from baseline to 6 months)
  • Stanford-Binet Intelligence Scales: 9 Months(Change from baseline to 9 months in IQ points)
  • Minnesota Executive Function Scale: 9 Months(Change from baseline to 9 months in t-score points)
  • NIH Toolbox Flanker Task: 9 Months(Change from baseline to 9 months in fully-corrected t-score points)
  • NIH Toolbox Flanker Task: 6 Months(Change from baseline to 6 months)
  • Child Behavior Checklist: 6 Months(Change from baseline to 6 months)
  • Child Behavior Checklist: 9 Months(Change from baseline to 9 months in t-score points)

Study Sites (1)

Loading locations...

Similar Trials